Additional Supplements
1 Medium-Chain Triglycerides (MCT)
Rationale. MCTs bypass normal fat digestion and are converted directly to ketones by the liver. Ketones provide alternative brain and muscle fuel, potentially bypassing impaired glucose metabolism.
Evidence. Theoretical for ME/CFS; moderate for cognitive support in other conditions.
Dosing. Start with 1 teaspoon and increase slowly to 1–2 tablespoons daily. Rapid introduction causes GI distress.
Energy Profile. Category A (net energy provider). Converts directly to ketone bodies in the liver, bypassing the carnitine transport system and providing immediate alternative fuel for brain and muscle. Ketogenesis from MCTs is metabolically efficient compared to long-chain fatty acid oxidation. Provides energy substrate that bypasses potentially impaired glucose metabolism pathways.
2 Quercetin + N-Acetylcysteine: Shared Oxidative–Th1 Terrain Stack
Certainty: 0.20 for mechanistic overlap; 0.10 for clinical efficacy in ME/CFS. Based on independent evidence for each agent’s mechanism in oxidative stress and Th1 modulation; no combined trial in ME/CFS exists. Research-stage only. Not yet replicated in ME/CFS.
This is a research-stage speculation. Neither quercetin nor NAC has completed an RCT specifically in ME/CFS for this indication. This entry does NOT constitute a clinical recommendation. Both are generally considered low-risk supplements, but quercetin has CYP3A4 inhibition potential (see drug interaction note below) and NAC may cause nausea or sulfur sensitivity in some ME/CFS patients.
Both lichen sclerosus and ME/CFS independently show elevated oxidative stress markers (8-hydroxydeoxyguanosine, malondialdehyde, reduced superoxide dismutase and glutathione) The shared oxidative terrain provides mechanistic rationale for targeting both simultaneously. Quercetin (a flavonoid bioflavonoid) attenuates IFN-γ-driven Th1 polarization in vitro and reduces IL-15 and TNF-α production; NAC restores glutathione and reduces TLR4-mediated NF-κB signaling — the same TLR4 axis implicated in LS and ME/CFS chronic inflammation. The combination targets both arms of the shared Th1/oxidative loop: quercetin suppresses the cytokine output; NAC depletes the oxidative amplification substrate.
Proposed research protocol: Quercetin 500 mg/day + NAC 1200 mg/day for 12 weeks in ME/CFS patients with documented oxidative stress markers at baseline (8-OHdG >8 ng/mg creatinine or MDA >2 µmol/L). Primary endpoint: reduction in 8-OHdG by ≥25%. Secondary endpoints: PEM frequency score, IL-15, NK cytotoxicity. If concurrent LS is present, LS symptom severity as an additional secondary endpoint.
Falsifiable prediction: The combination will reduce serum 8-OHdG by ≥25% in ME/CFS patients with baseline oxidative stress elevation; reduction will correlate with PEM frequency improvement (Spearman ρ > 0.4).
Drug interaction note: Quercetin inhibits CYP3A4 and CYP2C9; patients taking fludrocortisone, midodrine, or beta-blockers (common ME/CFS co-prescriptions) should have interactions reviewed before initiating. NAC is generally safe with ME/CFS co-medications; monitor for nausea in sulfur-sensitive patients. Start at low dose (quercetin 250 mg/day, NAC 600 mg/day) and titrate over 2 weeks.
Limitations: Both agents have independent evidence bases from heterogeneous conditions; ME/CFS-specific evidence is absent. The in vitro Th1 modulation data for quercetin does not predict clinical ME/CFS response. NAC has produced inconsistent results in fatigue-adjacent conditions. The combination is not currently standard of care for any indication; clinical trial infrastructure is required before any recommendation can be made. Certainty is intentionally low.
3 Resveratrol
Rationale. Activates sirtuins and AMPK; promotes mitochondrial biogenesis; antioxidant.
Evidence. Preliminary; animal studies promising but human data limited.
Dosing. 150–500 mg daily; trans-resveratrol is the active form.
Energy Profile. Category B (energy-neutral). Resveratrol activates SIRT1 and AMPK signaling pathways that promote mitochondrial biogenesis over weeks to months, but does not directly provide ATP substrates. Requires hepatic CYP450 metabolism (CYP1A2, CYP3A4) for glucuronidation and sulfation, imposing modest metabolic processing cost. Net effect is neutral in the short term; potential long-term energy benefit via increased mitochondrial mass is speculative.
4 Melatonin
Rationale.
- Sleep initiation and circadian rhythm regulation
- Potent antioxidant (especially mitochondrial)
- Immune modulation
- Anti-inflammatory
Evidence. Moderate for sleep; theoretical for other effects in ME/CFS.
Dosing.
- Sleep: 0.5–3 mg, 30–60 minutes before bed
- Some protocols use higher doses (5–20 mg) for antioxidant effects
- Extended-release forms for sleep maintenance issues
Note. “Less is more” for sleep—higher doses can paradoxically worsen sleep quality. Start at 0.5 mg.
Energy Profile. Category B (energy-neutral). Endogenous hormone with minimal hepatic processing at physiological replacement doses. Sleep improvement may indirectly enhance energy restoration during rest. No significant metabolic burden.
5 Pregnenolone
Pregnenolone is a neurosteroid synthesized from cholesterol, serving as the precursor for all other steroid hormones including DHEA, progesterone, cortisol, and testosterone.
Rationale.
- TRPM3 activation: Pregnenolone sulfate (PregS) is an endogenous activator of TRPM3 ion channels (see Section Novel Hypotheses from TRPM3 Ion Channel Research)
- Cognitive support: Enhances memory formation and retrieval; neuroprotective
- Neuronal myelination: Supports myelin synthesis and maintenance
- Fatigue relevance: Low pregnenolone levels have been reported in ME/CFS patients
- Immune modulation: Modulates neurotransmitter-gated channels in immune cells
TRPM3 Connection. Reduced TRPM3 function in ME/CFS NK cells has been demonstrated using pregnenolone sulfate stimulation. TRPM3 channels in ME/CFS patients show significantly reduced calcium flux when stimulated with PregS. Theoretically, increasing pregnenolone availability might partially compensate for channel dysfunction by increasing agonist concentration, though this remains speculative. The established finding is that TRPM3 dysfunction can be partially restored by low-dose naltrexone (LDN), which may explain LDN’s efficacy in some ME/CFS patients.
Evidence.
- Low pregnenolone levels documented in ME/CFS (clinical observations)
- No randomized controlled trials specifically in ME/CFS
- General evidence for cognitive and energy benefits in aging populations
- Theoretical basis from TRPM3 research
Dosing.
- Typical starting dose: 10–30 mg daily
- Some protocols use 50–100 mg daily
- Take in the morning (may be stimulating)
- Sublingual forms may have better absorption
Cautions.
- May affect hormone levels—caution in hormone-sensitive conditions
- Can be converted to androgens or estrogens depending on individual biochemistry
- Monitor for mood changes (anxiety, irritability)
- Avoid in pregnancy
- Consider baseline hormone testing before long-term use
Certainty: 0.20. No clinical trials have evaluated this combination; rationale is purely mechanistic extrapolation from separately-characterized TRPM3 effects of each agent.
Both pregnenolone sulfate and low-dose naltrexone influence TRPM3 function in ME/CFS, potentially through different mechanisms. Pregnenolone sulfate is a direct TRPM3 agonist, while LDN appears to restore TRPM3 responsiveness (mechanism not fully characterized). Theoretically, combining adequate pregnenolone levels with LDN might optimize TRPM3 function—the channel would be more responsive (LDN effect) and have adequate agonist (pregnenolone). No clinical trials have evaluated this combination, but given the favorable safety profiles of both, it represents a rational empirical approach for patients who have partial response to LDN alone.
Energy Profile. Category B–C (neutral to mildly demanding). Neurosteroid requiring hepatic CYP-mediated metabolism for conversion to downstream hormones (DHEA, progesterone, cortisol). Steroidogenesis is moderately energy-intensive. At supplemental doses, processing burden is modest but non-negligible.
6 Myo-Inositol (PIP2 Precursor Strategy)
Myo-inositol is the head-group precursor for phosphatidylinositol (PI) synthesis. PI is sequentially phosphorylated by PI4K and PIP5K to generate PIP2 (phosphatidylinositol 4,5-bisphosphate), a plasma membrane phospholipid required for the gating of multiple ion channels including TRPM3, TRPM7, Piezo channels, and KCNQ potassium channels.
Rationale.
- PIP2 precursor: If chronic GPCR autoantibody activity depletes PIP2 pools in ME/CFS immune cells (Section:pip2-depletion-convergence), myo-inositol supplementation theoretically supports PIP2 resynthesis by providing the rate-limiting substrate
- TRPM3 environment: Eaton-Fitch et al. (2021) demonstrated reduced TRPM3/PIP2 co-localization in ME/CFS NK cells; restoring membrane PIP2 levels could improve the channel gating environment independently of direct channel modulation
- Brain relevance: MRS studies have found altered cerebral myo-inositol levels in ME/CFS and fibromyalgia patients, suggesting disrupted phosphoinositide metabolism in the central nervous system
- Safety profile: Myo-inositol at 2–4 g/day is well-tolerated with established use in PCOS and depression research; no serious adverse effects at these doses
Evidence.
- No direct ME/CFS trials of myo-inositol for ion channel function
- Documented PIP2/TRPM3 co-localization deficit in ME/CFS NK cells
- PIP2 requirement for TRPM3 gating: established biochemistry
- Brain inositol alterations in ME/CFS: indirect evidence of phosphoinositide disruption
Inositol forms: which to use and which to avoid.
Not all commercially available inositol forms are interchangeable for PIP2 replenishment:
- Myo-inositol: The physiologically dominant isomer (>95% of the body inositol pool) and the direct precursor for phosphatidylinositol synthesis. The only appropriate form for PIP2 strategy. Available as powder at 2–4 g/day; well-tolerated; extensive safety data from PCOS and depression trials.
- D-chiro-inositol (DCI): A minor isomer (~3% of body pool) that participates in insulin signaling via GPI-linked mediators. DCI is not efficiently converted back to myo-inositol and does not directly support PIP2 synthesis. High DCI:myo ratios in the PCOS literature correlate with impaired outcomes. DCI is irrelevant for the PIP2 replenishment strategy described here.
- IP6 (inositol hexakisphosphate / phytic acid): Six phosphate groups must be removed sequentially before free myo-inositol is liberated — a slow process that occurs primarily in the gut. Meanwhile, IP6 strongly chelates Fe2+, Zn2+, Ca2+, and Mg2+ — minerals commonly deficient in ME/CFS. The mineral depletion risk outweighs any theoretical PIP2 benefit. Not recommended as a PIP2 replenishment strategy.
Dosing (research-stage rationale only).
- 2–4 g/day myo-inositol (most studied form for phosphoinositide support)
- Split into two doses; may be taken with food
- 8-week trial period to allow membrane remodeling
Cautions.
- GI tolerance issues (nausea, loose stools) are the primary dose-limiting factor; start at 1 g/day
- Inositol affects serotonin and dopamine receptor sensitivity; monitor for mood changes
- High doses may affect thyroid function; caution in thyroid conditions
Certainty: 0.25. Both approaches target TRPM3 dysfunction through different mechanisms: inositol replenishes the membrane lipid environment (PIP2 pool), while LDN restores channel gating responsiveness. If PIP2 depletion is an upstream contributor to TRPM3 dysfunction, inositol would address a cause that LDN alone cannot correct; LDN would additionally restore receptor-mediated channel activation. This combination is entirely theoretical and untested. Falsifiable prediction: In ME/CFS patients with documented TRPM3/PIP2 co-localization deficit, 8-week myo-inositol supplementation should increase PIP2/TRPM3 co-localization measured by immunofluorescence and improve NK cytotoxicity, with additive effect when combined with LDN.
Certainty: 0.30. Low-dose lithium inhibits IMPase/IMPA1, depleting free inositol and slowing PIP2 resynthesis — a potentially harmful effect in ME/CFS, where PIP2 is already depleted by GPCR autoantibody-driven PLC activity (Dual TRPM3+TRPM7 Dysfunction as a Subtype-Defining Signature). However, lithium’s inositol depletion simultaneously drives mTOR-independent autophagy via IP3 accumulation (Sade et al., 2016) and dampens NCS-1-amplified IP3R activity — effects that may be beneficial. Co-administration of myo-inositol could selectively restore the PIP2 pool via mass action (providing substrate downstream of the blocked IMPase) while preserving the IP3-driven autophagy benefit, because IP3 accumulation persists regardless of inositol levels when IMPase remains inhibited.
This pharmacological separation is non-obvious and mechanistically specific: inositol rescues the PIP2 arm without fully reversing lithium’s IP3/autophagy arm. It is directly testable: in ME/CFS PBMCs or iPSC-derived neurons treated with Li+ (0.5 mM) ± myo-inositol (10 mM), preserved autophagy flux (LC3-II/I ratio) with restored membrane PIP2 levels would confirm the separation. If inositol also abolishes the IP3/autophagy signal, the separation fails.
Not a clinical recommendation. This remains entirely pre-clinical rationale. No ME/CFS trial data for this combination exist.
(Certainty: 0.30 — mechanism established in cell models; ME/CFS-specific duality is inferential; pharmacological separation hypothesis is untested. Not yet replicated in ME/CFS context.)
Energy Profile. Category B (energy-neutral). Small organic molecule requiring minimal metabolic processing. Enzymatic phosphorylation to PIP2 is part of normal phospholipid metabolism.
7 Zinc
Rationale. Zinc is a trace mineral essential for gut barrier integrity, antioxidant protection in enterocytes, and neurotransmitter function. In the context of the enterochromaffin-vagal pathway (Wirth and Scheibenbogen 2025), zinc supports multiple nodes: (1) tight junction integrity reduces intestinal permeability and bacterial translocation; (2) antioxidant mechanisms in enterocytes that may protect enterochromaffin cells; (3) neurotransmitter synthesis and autonomic nerve function. Zinc is commonly depleted in ME/CFS due to malabsorption, chronic inflammation (acute-phase redistribution to liver), and reduced dietary diversity from fatigue limiting food preparation.
Forms.
- Zinc glycinate: Well-absorbed, gentle on GI tract
- Zinc carnosine: Combines zinc with carnosine dipeptide; additional mucosal healing properties; preferred for gut repair (see Chapter Action Plans for Mild to Moderate Cases)
- Zinc citrate or picolinate: Good bioavailability alternatives
- Avoid zinc oxide: Poor bioavailability
Dosing. 15–30 mg elemental zinc daily. Zinc carnosine 75 mg provides approximately 16 mg elemental zinc. Take away from or between meals for maximum absorption.
Cautions.
- Long-term zinc supplementation above 40 mg elemental zinc/day can deplete copper—monitor copper status with extended use or consider zinc-copper combination
- Take separately from calcium, magnesium, and iron (compete for absorption)
- Check serum zinc or RBC zinc before high-dose supplementation; levels may be misleadingly normal during inflammation despite tissue deficiency
Energy Profile. Category B (energy-neutral). Essential trace mineral and enzymatic cofactor absorbed through intestinal metallothionein pathways. Processing demands minimal at supplemental doses (15–30 mg). Supports immune function and wound healing without significant direct energy cost.
Certainty: 0.25. Zinc is released from glutamatergic presynaptic terminals and acts as an endogenous NMDA receptor antagonist at the GluN2A subunit. Zinc deficiency could disinhibit NMDA receptors, amplifying glutamatergic signalling. Also cofactor for GAD (GABA synthesis). Zinc picolinate or citrate 15-30mg/day. No ME/CFS data.
Falsifiable prediction. Low serum zinc (under 70 µg/dL) will predict response to zinc+Mg combination in ME/CFS with cognitive PEM.